Profound Medical Corp Stock Analysis
| PROF Stock | USD 5.68 0.13 2.34% |
200 Day MA 6.1438 | 50 Day MA 7.286 | Beta 0.387 |
Macro event markers
Profound Medical Corp appears undervalued based on a Real Value estimate of $7.18 and a Target Price of $11.9. A central aim of stock analysis is to estimate fair intrinsic value. This frames what Profound Medical Corp could be worth beyond short-term market pricing. Stock analysis typically draws on both fundamental and technical methods. Each method adds a different lens on value and price action.
Profound Medical Corp holds a debt-to-equity ratio of 0.018. Current projections place Short and Long Term Debt at 1.86 Million, representing a change of 15.84%. Last year, Profound Medical recorded Short and Long Term Debt of 1.56 Million. Higher debt levels can expand Profound Medical's financial risk exposure. Interest payments can affect earnings and coverage ratios over time. Asset vs Debt
Equity vs Debt
Price Book 6.244 | Enterprise Value Ebitda -5.75 | Price Sales 12.5125 | Shares Float 34.8 M | Wall Street Target Price 11.9 |
Profound Medical Corp reported an increase of $4.6 million in Net Income, $42.3 million in Net Income, and a net loss attributable to common shareholders of $27.1 million.
To explore further, visit Interest Expense and Depreciation And Amortization.
Stock Analysis Notes
About 45.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.32. Profound Medical Corp last dividend was issued on the 16th of October 2019. The company completed a 1:10 stock split on 16th of October 2019. Profound Medical Corp reported $192.9 million in Total Assets, a Return On Tangible Assets of -32.0%, and $0.10 in Asset Turnover.Gross Profit | 11.96 Million |
Investor Insights and Alerts
| Profound Medical generated a negative expected return over the last 90 days | |
| Profound Medical has high historical volatility and very poor performance | |
| Profound Medical Corp currently holds about 46.21 M in cash with -53.34 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21. | |
| Profound Medical has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13 Participate in ROTH Investor Conference on March 22-24 |
Largest EPS Surprises
Analyst consensus for Profound Medical is reset after each reporting cycle, making the beat-or-miss outcome a recurring catalyst. The direction and magnitude of the surprise both matter for near-term price action. For this stock, read EPS surprises with profitability quality and forward revisions.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-08-23 | 2017-06-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2016-11-16 | 2016-09-30 | -0.08 | -0.1 | -0.02 | 25 | ||
2016-05-06 | 2016-03-31 | -0.07 | -0.1 | -0.03 | 42 |
Environmental, Social, and Governance (ESG) Scores
ESG analysis for Profound Medical Corp is not only about values-based screening; it can also highlight operating practices and governance choices with real financial consequences. These scores become more relevant when they are compared against peers facing similar regulatory, labor, and supply-chain pressures.
Top Institutional Investors Holding Profound Stock
Institutional ownership matters in Profound Medical Corp because pension funds, mutual funds, banks, and advisers can materially influence liquidity, governance, and price discovery. Used correctly, institutional data helps investors understand who may be setting the marginal price and how resilient that holder base could be under stress.
| Shares | Penderfund Capital Management Ltd | 2025-09-30 | 9.4 K |
Market Capitalization
Profound Medical Corp enters market cap screens as a small-cap name with total equity value near 201.43 M across health care equipment & supplies companies. Supporting market cap data includes about 36.29 M shares outstanding, enterprise value near 182.43 M, and a workforce of about 162 people.Profitability
Profitability analysis for Profound Medical Corp should focus on how efficiently revenue converts into operating income, net income, and ultimately free cash flow that can be reinvested or returned to shareholders. Annual revenue is about 16.1 Million. Investors should compare gross, operating, and net margins rather than relying on one headline figure.
The company has Profit Margin (PM) of -2.64 %, which may suggest that it is unable to adequately control operational costs. This is significantly below industry benchmarks. Similarly, it shows Operating Margin (OM) of -1.23 %, which implies that for every $100 of revenue, it loses $1.23 at the operating level. | Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | -0.31 | -0.32 | |
| Return On Capital Employed | -0.31 | -0.33 | |
| Return On Assets | -0.31 | -0.32 | |
| Return On Equity | -0.65 | -0.69 |
Management Efficiency
The company has return on total asset (ROA) of -34.91 % which indicates that every $100 deployed in assets resulted in a loss of $34.91. This is significantly below industry benchmarks. Similarly, it shows a return on stockholder's equity (ROE) of -67.11 %, meaning that it produced losses on money invested by shareholders.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.01 | 3.42 | |
| Tangible Book Value Per Share | 3.01 | 3.16 | |
| Enterprise Value Over EBITDA | -4.40 | -4.62 | |
| Price Book Value Ratio | 3.58 | 3.80 | |
| Enterprise Value Multiple | -4.40 | -4.62 | |
| Price Fair Value | 3.58 | 3.80 | |
| Enterprise Value | 250.2 M | 267.7 M |
When investors examine management execution at Profound Medical Corp, they are looking for evidence that strategy, financial discipline, and operating results are moving in the same direction. The business currently sits in the Healthcare sector and the Medical Devices industry. Current market capitalization is about 201.43 Million, enterprise value is near 182.43 Million, and annual revenue is around 16.1 Million.
Operating Margin | Long Term Debt Total | Three Month Return -24.28 | Short Long Term Debt Total | Ten Year Return -42.84 |
Technical Drivers
As of the 13th of March 2026, Profound Medical maintains a quoted price of 5.68 per share. Short-term indicators show Risk Adjusted Performance of -0.01, variance of 25.54, and Coefficient Of Variation of -4,185. The model measures trend continuation and reversal probability using historical patterns. Comparative analytics measure deviation from sector averages.Profound Medical Corp Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Profound Medical Corp price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
Insider Trading Activities
Insider trading disclosures for Profound Medical Corp offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 201.43 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
Menawat Arun Swarup over six months ago Acquisition by Menawat Arun Swarup of 12027 shares of Profound Medical at 4.73 subject to Rule 16b-3 | ||
Menawat Arun Swarup over six months ago Acquisition by Menawat Arun Swarup of 10003 shares of Profound Medical at 4.325 subject to Rule 16b-3 | ||
Hofer Michael over a year ago Acquisition by Hofer Michael of 500000 shares of Profound Medical at 0.0014 subject to Rule 16b-3 |
Outstanding Bonds
Reviewing Profound Medical Corp bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Predictive Daily Indicators
Daily trading signals in Profound Medical Corp help active traders monitor momentum, reversals, and volume pressure while the session is still developing. The better setups usually come from combining these signals with strict risk limits, because short-term data can reverse quickly when liquidity thins.
Forecast Models
Quantitative forecast tools for Profound Medical Corp focus on patterns in observed data, which makes them especially useful when the market is moving faster than traditional bottom-up research can refresh. Used well, forecast models can complement fundamental research by showing where observed price behavior still supports or contradicts the discretionary thesis.Financial Strength and Earnings Quality Indicators
Profound Medical Corp financial ratings play a critical role in determining how much Profound Medical have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Profound Medical's borrowing costs.| Piotroski F Score | 2 | Frail | View |
| Beneish M Score | -2.40 | Unlikely Manipulator | View |
Debt to Cash Allocation
Tracking debt and cash allocation over time can show when Profound Medical is prioritizing expansion, refinancing, or capital return.
Profound Medical Corp currently holds $6.45 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest Profound Medical Corp is not taking enough advantage from borrowing. Profound Medical Corp has a current ratio of 17.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Profound Medical's use of debt, we should always consider it together with its cash and equity.Total Assets Over Time
Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Profound Medical uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Profound Medical Debt Ratio | 3.18 |
Corporate Bonds Issued
Bond maturity for Profound Medical is a core risk dimension. Longer duration can offer higher yield, but price sensitivity and credit uncertainty also increase.
Profound Short Long Term Debt Total
Short Long Term Debt Total | 6.78 Million |
Stock Analysis Methodology
Profound Medical stock analysis integrates balance sheet strength, earnings quality, and price momentum. Profound Medical trades at P/B of 6.24, P/S of 12.51. Profitability metrics show ROE of -67.11%, net margin of -2.64%, operating margin of -123.29%. Balance sheet indicators include debt-to-equity of 0.02 and current ratio of 17.36. Financial distress probability is estimated at 5%, indicating low near-term solvency risk. Beta of 1.4751 suggests moderate market correlation. A negative Sharpe ratio of -0.0682 indicates returns below the risk-free rate over the measurement period. Profound Medical has a market cap of 201.43 M, ROE of -67.11%.
This section for Profound Medical Corp is built from periodic company reporting and market reference feeds, with harmonization applied to align reporting definitions. Analyst inputs may be included when coverage is available. Values may update on different source schedules.
This content is curated and reviewed by:
Michael Smolkin - Member of Macroaxis Board of DirectorsCurrent Profound Analyst Rating Consensus
| Target Price | Consensus | # of Analysts | |
| 11.9 | Strong Buy | 5 | Odds |
Analyst recommendations for Profound Medical Corp are summarized across multiple research providers. It also summarizes the average analyst consensus. The number of analysts covering Profound Medical Corp reflects its institutional relevance. Broader coverage typically means more information about Profound is available to the market, potentially improving price efficiency.
Profound Stock Analysis Indicators
Diagnostics snapshot includes 14 indicators such as Begin Period Cash Flow, Common Stock Shares Outstanding, Total Stockholder Equity.
| Begin Period Cash Flow | 75.3 M | |
| Common Stock Shares Outstanding | 30.2 M | |
| Total Stockholder Equity | 91 M | |
| Total Cashflows From Investing Activities | -337.9 K | |
| Property Plant And Equipment Net | 225 K | |
| Cash And Short Term Investments | 81.8 M | |
| Cash | 81.8 M | |
| Accounts Payable | 2.1 M | |
| Net Debt | -75.3 M | |
| 50 Day M A | 7.286 | |
| Total Current Liabilities | 8.3 M | |
| Other Operating Expenses | 57.4 M | |
| Non Current Assets Total | 88.7 M | |
| Non Currrent Assets Other | 88 M |
Popular Tools for Profound Stock analysis
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |